Project Grant R43AG084351
Award Date
8/15/23
Completion Date
7/31/24
Dollars Obligated
$277K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
Amdx Prognostx Inc. received a $791,145 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases within the Department of Health and Human Services. The award falls under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), which promotes biomedical research to improve understanding and treatment of diabetes, digestive, and kidney diseases. Under this award, Amdx Prognostx will develop an enzyme-linked immunosorbent assay...
This $1,274,632 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of CUTANA-RH, a novel platform for genome-wide profiling of R-loops to accelerate aging and neurodegenerative disease research. The key products and services to be delivered under this 21-month grant include: Developing a modular immunotethering strategy for genomic mapping of R-loops, which leverages a catalytically inactive RNase H1 enzyme as a highly...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $448,961 to Telohealthdx LLC to develop a low-cost, accurate, and high-throughput DNA array and fluorescent in situ hybridization (FISH)-based method to measure the absolute lengths of individual telomeres. The goal is to create an improved diagnostic test for telomere-associated diseases, which are prevalent among the aging population and include conditions like dyskeratosis congenita, aplastic...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...
The General Hospital Corporation (MGH) Research Management Division was awarded a $458,585 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to develop a method for detecting autoantibodies against beta-amyloid in serum as a potential biomarker for Alzheimer's disease (AD). The 2-year project aims to investigate the use of small molecule compounds called CRANAD-XS to differentially tune the binding between beta-amyloid and its...
This $500,000 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) will support Sxrna Technologies, Inc. in developing an organoid toolkit for Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD). The company aims to create a platform for identifying senescent cells in living tissue, which can provide insights into the aging process and enable high-throughput drug screening in complex 3D tissue models. Specifically, the grant will fund...
This $326,797 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) aims to identify proteomic (protein-based) biomarkers that can predict risk of cognitive impairment in individuals with type 2 diabetes. The primary goal is to use proteomic analyses to discover plasma protein differences and networks associated with newly diagnosed mild cognitive impairment in this population. The project will also examine how these proteins relate to preclinical...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $725,420 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop an optimized allysine-targeted positron emission tomography (PET) probe and validate it in animal models and human renal biopsy samples. The goal is to establish a non-invasive...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $500,928 to Pupil Bio, Inc. to develop an early detection test for Type 1 Diabetes (T1D) using next-generation sequencing (NGS) analysis of cell-free DNA (cfDNA) methylation patterns specific to pancreatic beta cells. The goal is to create a non-invasive diagnostic tool that can identify the early stages of T1D...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training (CFDA 93.859) program provides $350,000 to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California, to develop and demonstrate a novel enzyme-based, single-molecule protein sequencing system. The proposed technology aims to enable scalable, multiplexed protein sequencing with high accuracy and throughput, surpassing the...